Gynecologic Cancers

Elevated levels of neopterin were found to be significantly associated with poorer survival outcomes in patients with ovarian cancer.

Researchers are hoping that adding a checkpoint inhibitor to the treatment armamentarium may help improve outcomes in patients with locally advanced or metastatic disease epithelial ovarian cancer.

A small study has found an increased risk for serous or serous-like endometrial carcinoma among women with BRCA1 mutations after undergoing risk-reducing salpingo-oophorectomy without hysterectomy.

A large, prospective analysis showed that risk factors for ovarian cancer demonstrate substantial heterogeneity in their associations with histologic subtypes of the disease.

Researchers were able to molecularly classify endometrial cancers with distinct survival differences using a new classification tool called ProMisE that uses clinically applicable methods.

A concurrent chemotherapy and radiotherapy regimen with cisplatin and paclitaxel yielded a good response rate and strong long-term survival outcomes in patients with locally advanced or recurrent cervical cancer.

A live attenuated bioengineered bacteria-vectored vaccine immunotherapy is well tolerated and appears to be associated with promising overall survival among women with persistent/recurrent metastatic cervical cancer.

Despite hematologic toxicities and port-related adverse events, IP carboplatin plus IV dose-dense paclitaxel appears to be effective in patients with suboptimally debulked epithelial ovarian or primary peritoneal carcinoma.

Pembrolizumab is well-tolerated and shows promising antitumor activity and early survival rates among patients with PD-L1–positive cervical squamous cell cancer, according to preliminary results of the KEYNOTE-028 trial.

Extending platinum-free interval with pegylated liposomal doxorubicin, topotecan, or gemcitabine does not improve overall survival among patients with recurrent ovarian cancer.

Baseline quality of life measures predict early cessation of chemotherapy and overall survival in women with platinum-resistant/refractory, recurrent ovarian cancer.

Hormone maintenance therapy is associated with better survival than post-treatment surveillance for women with low-grade serous carcinoma of the ovary or peritoneum.

Among women previously treated with neoadjuvant chemotherapy followed by debulking surgery for advanced epithelial ovarian cancer, adding intraperitoneal to intravenous administration of postsurgical chemotherapy appears to be associated with a lower rate of disease progression.

Testing for HPV infections in urine could be an extremely accurate way to exclude the possibility of such infections and screen for cervical cancer.

ASCO has released a clinical practice guideline on invasive cervical cancer. For the first time, ASCO created the guideline based on resource availability, tailoring recommendations to support basic- or limited-resource settings.

Women who do not engage in regular physical activity have an increased risk of developing cervical cancer, according to a new study

In 2016, it is estimated that there will be 22,280 newly diagnosed cases of ovarian cancer in the United States. Astonishing as it may seem, the lifetime risk for a woman developing ovarian cancer is 1 in 75, with a risk of death related to the disease being 1 in 100 (excluding low malignant potential tumors).

It may be possible to remove deleterious germline BRCA1 mutations through alternative mRNA splicing and prevent drug resistance in some breast and ovarian cancer patients.

NEW ORLEANS – A new type of antibody-drug conjugate (ADC) platform may pave the way to help patients with ovarian cancer and non-small cell lung cancer.

The American Society of Clinical Oncology released a statement calling for the rapid expansion of use of the human papillomavirus (HPV) vaccine to help protect thousands of people from HPV-associated cancers.

The combination of sentinel lymph node mapping and use of uterine intraoperative restrictive frozen section in patients with low-grade endometrial cancer can reduce the rate of complete lymphadenectomy without reducing the detection of lymphatic metastasis.

Loss of function of the PTEN tumor suppressor gene leads to resistance to therapies targeting the Notch signaling pathway according to a mouse study presented at the 2016 Society of Gynecologic Oncology annual meeting, held in San Diego, March 19-22, 2016.

Combining three markers of homologous recombination deficiency into a single score may improve treatment decisions for women with ovarian cancer, according to a study reported at the 2016 SGO Annual Meeting.

A 42-year-old woman presents with excess uterine bleeding. After a biopsy is performed, what is your diagnosis?

Ovarian cancer is a complex disease, comprised of many forms of degrees of aggression. Statistics for ovarian cancer remain startling and include 21,000 new cases annually in the United States and a staggering 14,000 deaths.

Assignment to a dose-dense regimen of paclitaxel given weekly did not prolong progression-free survival compared with paclitaxel given every 3 weeks in a group of patients with ovarian cancer treated with or without bevacizumab.

This review focuses on the clinicopathologic and molecular features of epithelial ovarian cancer, with specific attention to genetic predisposition, morphologic challenges, immunohistochemistry, and molecular features.

The movement of ovarian carcinoma histotypes from ill-defined and poorly reproducible clusters of cases to distinct disease entities clearly has beneficial implications for patient management.

In this review, we will summarize clinical trials that have used various immunotherapeutic strategies, with a particular focus on recently emerging data for new agents and combinations.

Adolescent girls who live in predominantly Hispanic and high poverty communities are more likely to have had at least one HPV vaccine dose compared to girls in low poverty communities and those with different ethnic make up.